The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.The reported patient effect of syncope is not listed in the xience sierra everolimus eluting coronary stent systems instructions for use (ifu) as a known patient effect of coronary procedures; however, syncope is listed in the no-fault errors for coronary and endovascular products risk assessment (ram) as a foreseeable event.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
It was reported that on (b)(6) 2020 a xience sierra stent was implanted.On (b)(6) 2020, patient was re-admitted with post-procedural cardiac disturbances.Bypass surgery was performed.On (b)(6) 2020, patient was re-admitted with syncope and collapse.The final patient outcome is unknown.No additional information was provided.
|